Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$10.26 USD

10.26
1,183,920

+0.28 (2.81%)

Updated Sep 11, 2024 04:00 PM ET

After-Market: $10.26 0.00 (0.00%) 5:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

National Vision (EYE) Q2 Earnings Top Estimates, 2021 View Up

Strength in Americas Best and Eyeglass World brands drove National Vision's (EYE) revenues in the second quarter of 2021.

National Vision (EYE) Surpasses Q2 Earnings and Revenue Estimates

National Vision (EYE) delivered earnings and revenue surprises of 108.70% and 11.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) to Report Q2 Earnings: What's in Store?

National Vision (EYE) is expected to report sequentially better results for the second quarter on gradual reopening of stores and return toward more normal operations.

National Vision (EYE) Earnings Expected to Grow: Should You Buy?

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes

National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.

OPKO Health (OPK) Inks Licensing Deal for AntagoNAT Technology

OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.

Inogen (INGN) Hits New 52-Week High: What's Driving It?

Investors are optimistic about Inogen's (INGN) direct-to-customer business model and a strong product portfolio.

QIAGEN (QGEN) Stock Falls on Downbeat Full-Year Guidance

According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.

NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes

We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.

Riya Anand headshot

3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19

Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.

Medtronic (MDT) Reports Economic Findings on PRODIGY Data

Medtronic (MDT)-sponsored PRODIGY Trial data was used to analyze cost benefits and outcomes from continuous pulse oximetry and capnography monitoring in high-risk patients.

BD's (BDX) Digital Marketplace Set to Improve User Experience

BD's (BDX) latest online marketplace is expected to offer a better user experience to its flow cytometry users.

Philips (PHG)-Cognizant Collaborate to Develop Health Solutions

Philips (PHG) is collaborating with Cognizant to develop health solutions that will help healthcare and life science companies provide improved patient care and accelerate clinical trial procedure.

McKesson (MCK) Enters Deal to Divest Some European Businesses

McKesson (MCK) to sell off some of its European ventures to streamline its business and prioritize investments in areas where it has better expertise.

Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow

Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.

Masimo (MASI) Reports Study Findings Backing the SedLine

Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.

Zacks.com featured highlights include: Intuit, National Vision, Lindsay Corp, Magnolia Oil & Gas and Buckle

Zacks.com featured highlights include: Intuit, National Vision, Lindsay Corp, Magnolia Oil & Gas and Buckle

Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?

Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.

Medtronic's (MDT) DEFINE AFib Study to Assess AF Burden

Medtronic (MDT) begins first app-based study to understand atrial fibrillation burden in patients, utilizing data collected from the LINQ range of insertable cardiac monitors.

5 Top-Performing Liquid Stocks for Attractive Returns in 2021

Here are five top-ranked liquid stocks -- Intuit (INTU), National Vision (EYE), Lindsay Corporation (LNN), Magnolia Oil & Gas (MGY) and Buckle (BKE) -- which investors can tap for attractive returns.

Bio-Rad (BIO)-Seegene Pact to Provide Diagnostic Suit In U.S.

Bio-Rad (BIO) and Seegene team up to develop and commercialize molecular diagnostic products in the United States.

West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?

Investors are optimistic about West Pharmaceutical's (WST) solid proprietary products segment.

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.

Bowen Center Expands Access to Care via NextGen's (NXGN) Platform

NextGen's (NXGN) platform is likely to expand care to the underserved patient pool by improving the access to and delivery of whole-person care.

Amedisys' (AMED) Contessa Buyout to Boost Home Health Business

Amedisys (AMED) inks deal to acquire Contessa Health to boost home health and hospice services business.